Journal: Stem Cell Research & Therapy

Article Title: Human umbilical cord mesenchymal stem cells ameliorate colon inflammation via modulation of gut microbiota-SCFAs-immune axis

doi: 10.1186/s13287-023-03471-9

Figure Lengend Snippet: HUMSCs ameliorated DSS-induced experimental colitis. a The phenotype of MSCs was identified with high expression of MSCs markers, including CD90, CD44, CD29, and CD73, CD105, but negative for the expression of leukocyte markers, including CD45 and HLA-DR. b Diagram illustrating the experimental design employed in this study. Mice were treated with 2% DSS in their drinking water for 7 days followed by 3 days of normal water. MSCs (1 × 10 6 cells) suspended in PBS were administered by intraperitoneal (i.p.) injection in DSS/MSC group mice on day 5 of the study. While the Control and DSS groups of mice were administered with the same volume of PBS by i.p. injection. c Daily body weight change (n = 6). d Disease activity index (DAI) score (n = 6). e Survival (n = 13). f Representative pictures of colon and colon length (n = 6). g Representative microscopic pictures of H&E staining (40× and 100× magnification) and histopathological score (n = 6). Data were presented as means ± SD. P values were calculated by one-way analysis of variance (ANOVA) followed by Tukey's test, * p < 0.05; ** p < 0.01; *** p < 0.001

Article Snippet: Human umbilical cord mesenchymal stem cells (HUMSCs) purchased from Cyagen Biosciences (Guangzhou, China) were cultured in a MSC medium (OriCell®, Cyagen Biosciences, Guangzhou, China) at 37 °C in a 5% CO2 incubator.

Techniques: Expressing, Injection, Activity Assay, Staining

Journal: Stem Cell Research & Therapy

Article Title: Human umbilical cord mesenchymal stem cells ameliorate colon inflammation via modulation of gut microbiota-SCFAs-immune axis

doi: 10.1186/s13287-023-03471-9

Figure Lengend Snippet: HUMSCs shaped intestinal immune responses through regulating Treg/Th2/Th17 balance and altering the cytokine profile. a Heatmap of cytokine mRNA relative expression levels from colon tissue measured by cytokine microarray. b Volcano plot of cytokine differential expression from colon tissue in DSS/PBS group compared to DSS/MSC group (fold-change > 1.3, P < 0.05). n = 6 each group. p values were calculated using Unpaired T-test. c IL-17A, IL-6, IL-1β, CCL5, and IL-10 cytokines levels in colon tissue homogenate were measured by ELISA among Control, DSS/PBS and DSS/MSC groups (n = 6). Treg (CD4 + CD25 + Foxp3 + ) ( d ), Th2 (CD4 + IL-4 + ) ( e ), Th17 (CD4 + IL-17A + ) ( f ), and Th1 (CD4 + IFN-γ + ) ( g ) cells in the colonic LP and MLN from Control, DSS/PBS and DSS/MSC groups were analyzed by flow cytometry and bar charts of the percentages of cells were displayed (n = 5). Data were presented as means ± SD. P values were calculated by ANOVA followed by Tukey's test. * p < 0.05; ** p < 0.01, *** p < 0.001, NS indicates p > 0.05

Article Snippet: Human umbilical cord mesenchymal stem cells (HUMSCs) purchased from Cyagen Biosciences (Guangzhou, China) were cultured in a MSC medium (OriCell®, Cyagen Biosciences, Guangzhou, China) at 37 °C in a 5% CO2 incubator.

Techniques: Expressing, Microarray, Enzyme-linked Immunosorbent Assay, Flow Cytometry

Journal: Stem Cell Research & Therapy

Article Title: Human umbilical cord mesenchymal stem cells ameliorate colon inflammation via modulation of gut microbiota-SCFAs-immune axis

doi: 10.1186/s13287-023-03471-9

Figure Lengend Snippet: HUMSCs treatment significantly remodeled the gut microbiota diversity and composition. Histograms of relative abundance for top 10 microbes at the phylum ( a ) and family ( b ) levels. c Histograms of relative abundance for top 30 microbes at the genus level. Alpha diversity boxplot of chao1 index ( d ), pielou_e index ( e ), and shannon index ( f ). g Principal coordinate analysis (PCoA) based on weighted UniFrac distances for beta diversity. h Non-Metric Multi-Dimensional Scaling (NMDS) based on weighted UniFrac distances for beta diversity. i Venn diagram displaying the common and unique ASVs among Control, DSS/PBS and DSS/MSC groups. j Analysis of differences in the microbial taxa among the three groups was shown using LEfSe (LDA coupled with effect size measurements). k Based on the ASVs abundance at the genus level, a volcano plot was organized for the analysis of differential microbiota between DSS/PBS and DSS/MSC groups using Metastats analysis (fold-change > 2, P < 0.05). Blue nodes denote significantly up-regulated genera in DSS/MSC group, and red nodes represent significantly up-regulated genera in DSS/PBS group. n = 6 mice per group

Article Snippet: Human umbilical cord mesenchymal stem cells (HUMSCs) purchased from Cyagen Biosciences (Guangzhou, China) were cultured in a MSC medium (OriCell®, Cyagen Biosciences, Guangzhou, China) at 37 °C in a 5% CO2 incubator.

Techniques:

Journal: Stem Cell Research & Therapy

Article Title: Human umbilical cord mesenchymal stem cells ameliorate colon inflammation via modulation of gut microbiota-SCFAs-immune axis

doi: 10.1186/s13287-023-03471-9

Figure Lengend Snippet: The protective effect of HUMSCs on colon inflammation was abrogated by antibiotic treatment. a Diagram illustrating the mouse model of colitis employed in this study. Wild-type mice were gavaged using broad-spectrum antibiotic (ABX) once a day for 5 days to deplete gut microbiota, and then 2% DSS drinking water was administered for 7 days to induce colitis. ABX/DSS/MSC group mice were treated with 1 × 10 6 HUMSCs (i.p.) on day 5, and ABX/DSS/PBS and ABX/Control group mice were delivered an equal volume of vehicle in the same way. b Daily body weight change (n = 6). c DAI score (n = 6). d Survival (n = 13). e Representative pictures of colon and colon length (n = 6). f Representative microscopic pictures of H&E staining (100× magnification) and histopathological score (n = 6). g IL-17A, IL-6, IL-1β, CCL5, and IL-10 cytokines levels in colon tissue homogenate were measured by ELISA between ABX/DSS/PBS and ABX/DSS/MSC groups (n = 6). h Representative flow cytometric analysis of Treg, Th2, and Th17 cells in the colonic LP and MLN from ABX/DSS/PBS and ABX/DSS/MSC groups. i Bar charts of the percentages of Treg, Th2, and Th17 cells in the colonic LP and MLN were displayed (n = 5). Data were presented as means ± SD. P values were calculated using Unpaired T-test, NS indicates p > 0.05

Article Snippet: Human umbilical cord mesenchymal stem cells (HUMSCs) purchased from Cyagen Biosciences (Guangzhou, China) were cultured in a MSC medium (OriCell®, Cyagen Biosciences, Guangzhou, China) at 37 °C in a 5% CO2 incubator.

Techniques: Staining, Enzyme-linked Immunosorbent Assay

Journal: Stem Cell Research & Therapy

Article Title: Human umbilical cord mesenchymal stem cells ameliorate colon inflammation via modulation of gut microbiota-SCFAs-immune axis

doi: 10.1186/s13287-023-03471-9

Figure Lengend Snippet: Fecal microbial transplants from HUMSCs-treated mice inhibited colitis. a Diagram illustrating the mouse model of colitis employed in this study. The feces from Control, DSS/PBS and DSS/MSC groups mice were transplanted into ABX-mice via intragastric administration once a day for 5 days, and then followed by DSS treatment after three days of rest. b Body weight change (n = 6). c DAI score (n = 6). d Survival (n = 12). e Representative pictures of colon and colon length (n = 6). f Representative microscopic pictures of H&E staining (40× and 100× magnification) and histopathological score (n = 6). g IL-17A, IL-6, IL-1β, CCL5, and IL-10 cytokines levels in colon tissue homogenate were measured by ELISA among FMT(Control), FMT(DSS), and FMT(MSC) groups (n = 6). h Representative flow cytometric analysis of Treg, Th2, and Th17 cells in the colonic LP and MLN from FMT(Control), FMT(DSS), and FMT(MSC) groups. i Bar charts of the percentages of Treg, Th2, and Th17 cells in the colonic LP and MLN were displayed (n = 5). Data were presented as means ± SD. P values were calculated by ANOVA followed by Tukey's test, * p < 0.05; ** p < 0.01; *** p < 0.001, NS indicates p > 0.05

Article Snippet: Human umbilical cord mesenchymal stem cells (HUMSCs) purchased from Cyagen Biosciences (Guangzhou, China) were cultured in a MSC medium (OriCell®, Cyagen Biosciences, Guangzhou, China) at 37 °C in a 5% CO2 incubator.

Techniques: Staining, Enzyme-linked Immunosorbent Assay

Journal: Stem Cell Research & Therapy

Article Title: Human umbilical cord mesenchymal stem cells ameliorate colon inflammation via modulation of gut microbiota-SCFAs-immune axis

doi: 10.1186/s13287-023-03471-9

Figure Lengend Snippet: HUMSCs administration transformed microbiota-derived short-chain fatty acids (SCFAs) profiles. a Fecal SCFAs concentrations from the Control, DSS/PBS and DSS/MSC groups mice (n = 6). Data were presented as means ± SD. P values were calculated by ANOVA followed by Tukey's test, * p < 0.05; ** p < 0.01; *** p < 0.001, NS indicates p > 0.05. b Sankey diagram displaying visually the association between gut microbes and fecal SCFAs profiles. The connection line represents the correlation, the red color denotes the positive correlation, and the blue denotes the negative correlation. c Heatmap showing the correlation between differentially enriched microbes and SCFAs profiles. The red color denotes a positive correlation, while blue color denotes a negative correlation. The intensity of the color is proportional to the strength of Pearson correlation. * P < 0.05. d Fecal SCFAs concentrations from the FMT (Control), FMT (DSS) and FMT (MSC) groups mice (n = 5). Data were presented as means ± SD. P values were calculated by ANOVA followed by Tukey's test, * p < 0.05; ** p < 0.01; *** p < 0.001, NS indicates p > 0.05

Article Snippet: Human umbilical cord mesenchymal stem cells (HUMSCs) purchased from Cyagen Biosciences (Guangzhou, China) were cultured in a MSC medium (OriCell®, Cyagen Biosciences, Guangzhou, China) at 37 °C in a 5% CO2 incubator.

Techniques: Transformation Assay, Derivative Assay

Journal: Stem Cell Research & Therapy

Article Title: Human umbilical cord mesenchymal stem cells ameliorate colon inflammation via modulation of gut microbiota-SCFAs-immune axis

doi: 10.1186/s13287-023-03471-9

Figure Lengend Snippet: Sterile fecal filtrate (SFF) from HUMSCs-treated mice attenuated DSS-induced colitis. a Diagram illustrating the mouse model of colitis employed in this study. The fecal supernatant from DSS/PBS and DSS/MSC groups mice was centrifuged and then passed through 0.22 μm filters to obtain sterile fecal filtrate (SFF) with different concentrations of SCFAs. ABX-mice were then gavaged using SFF for continuous 10 days. And another group mice were orally administered with a mixture of SCFAs including acetate (A), propionate (P) and butyrate (B) as a positive control. b Body weight change (n = 6). c DAI score (n = 6). d Survival (n = 12). e Representative pictures of colon and colon length (n = 6). f Representative microscopic pictures of H&E staining (40× and 100× magnification) and histopathological score (n = 6). g IL-17A, IL-6, IL-1β, CCL5, and IL-10 cytokines levels in colon tissue homogenate were measured by ELISA among SFF(DSS), SFF(MSC) and SCFAs groups (n = 6). h Representative flow cytometric analysis of Treg, Th2, and Th17 cells in the colonic LP and MLN from SFF(DSS), SFF(MSC) and SCFAs groups. i Bar charts of the percentages of Treg, Th2, and Th17 cells in the colonic LP and MLN were displayed (n = 5). Data were presented as means ± SD. P values were calculated by ANOVA followed by Tukey's test, * p < 0.05; ** p < 0.01; *** p < 0.001, NS indicates p > 0.05

Article Snippet: Human umbilical cord mesenchymal stem cells (HUMSCs) purchased from Cyagen Biosciences (Guangzhou, China) were cultured in a MSC medium (OriCell®, Cyagen Biosciences, Guangzhou, China) at 37 °C in a 5% CO2 incubator.

Techniques: Sterility, Positive Control, Staining, Enzyme-linked Immunosorbent Assay

Journal: Stem Cell Research & Therapy

Article Title: Human umbilical cord mesenchymal stem cells ameliorate colon inflammation via modulation of gut microbiota-SCFAs-immune axis

doi: 10.1186/s13287-023-03471-9

Figure Lengend Snippet: SCFAs regulated the immune inflammatory response in ABX-colitis mice. a Fecal SCFAs concentrations from the SFF(DSS) and SFF(MSC) groups mice (n = 5). Data were presented as means ± SD. P values were calculated using Unpaired T-test, * p < 0.05; ** p < 0.01; *** p < 0.001, NS indicates p > 0.05. b Heatmap showing the correlation between SCFAs and cytokine among the three model systems including the model of colitis treated with HUMSCs or not, the FMT model, and SFF model systems. The red color denotes a positive correlation, while blue color denotes a negative correlation. The intensity of the color is proportional to the strength of Pearson correlation. * p < 0.05; ** p < 0.01; *** p < 0.001

Article Snippet: Human umbilical cord mesenchymal stem cells (HUMSCs) purchased from Cyagen Biosciences (Guangzhou, China) were cultured in a MSC medium (OriCell®, Cyagen Biosciences, Guangzhou, China) at 37 °C in a 5% CO2 incubator.

Techniques:

Journal: International Journal of Molecular Sciences

Article Title: State of the Art Review of Cell Therapy in the Treatment of Lung Disease, and the Potential for Aerosol Delivery

doi: 10.3390/ijms21176435

Figure Lengend Snippet: Overview of in-vitro differentiation of MSCs (mesenchymal stromal cells). Note: Figure created with BioRender.com.

Article Snippet: NCT04347967 , Mesenchymal stem cells for the treatment of Acute Respiratory Distress Syndrome (ARDS) , Not recruiting yet , Meridigen Biotech Co. Ltd. , ARDS , Intravenous Infusion , Participants will receive low, medium, and high doses of UMC119-06 given to 3 different set of people , N/A , 1.

Techniques: In Vitro

Journal: International Journal of Molecular Sciences

Article Title: State of the Art Review of Cell Therapy in the Treatment of Lung Disease, and the Potential for Aerosol Delivery

doi: 10.3390/ijms21176435

Figure Lengend Snippet: Overview of the several paracrine factors secreted by MSCs that can attenuate lung injury. Note: Figure created with BioRender.com.

Article Snippet: NCT04347967 , Mesenchymal stem cells for the treatment of Acute Respiratory Distress Syndrome (ARDS) , Not recruiting yet , Meridigen Biotech Co. Ltd. , ARDS , Intravenous Infusion , Participants will receive low, medium, and high doses of UMC119-06 given to 3 different set of people , N/A , 1.

Techniques:

Journal: International Journal of Molecular Sciences

Article Title: State of the Art Review of Cell Therapy in the Treatment of Lung Disease, and the Potential for Aerosol Delivery

doi: 10.3390/ijms21176435

Figure Lengend Snippet: Mesenchymal stem cell (MSC)-based therapy clinical trials for ARDS (acute respiratory distress syndrome).

Article Snippet: NCT04347967 , Mesenchymal stem cells for the treatment of Acute Respiratory Distress Syndrome (ARDS) , Not recruiting yet , Meridigen Biotech Co. Ltd. , ARDS , Intravenous Infusion , Participants will receive low, medium, and high doses of UMC119-06 given to 3 different set of people , N/A , 1.

Techniques: Clinical Proteomics, Derivative Assay, Infection, Virus

Journal: International Journal of Molecular Sciences

Article Title: State of the Art Review of Cell Therapy in the Treatment of Lung Disease, and the Potential for Aerosol Delivery

doi: 10.3390/ijms21176435

Figure Lengend Snippet: MSC-based therapy clinical trials for sepsis.

Article Snippet: NCT04347967 , Mesenchymal stem cells for the treatment of Acute Respiratory Distress Syndrome (ARDS) , Not recruiting yet , Meridigen Biotech Co. Ltd. , ARDS , Intravenous Infusion , Participants will receive low, medium, and high doses of UMC119-06 given to 3 different set of people , N/A , 1.

Techniques: Clinical Proteomics, Control